AMG 430 / Amgen - LARVOL DELTA

Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases (WBC 2025) - "Here we characterize the inhalable Jagged-1 targeting tool Anticalin, PRS-400, in comparison to a monoclonal anti-JAG1 antibody AMG 430 in in vitro (human) and in vivo (murine) models In vitro: PRS-400 dose-dependent suppressed JAG1-notch signalling in a human luciferase reporter system.In human ALI cultures PRS-400 penetrated mucus, suppressed FOXA3+ goblet cell metaplasia and epithelial remodelling induced by IL-13 and IL-17 and restored FOXJ1+ ciliated cells. Targeting the Jagged-1/Notch-2 signalling axis by inhalation, exemplified by PRS-400, shows great potential for the treatment of muco-obstructive lung diseases."

Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • FOXA3 • IL13 • IL17A • JAG1 • NOTCH2

Targeting the Jagged-1/Notch pathway for the treatment of muco-obstructive lung diseases (WBC 2025) - "Here we characterize the inhalable Jagged-1 targeting tool Anticalin, PRS-400, in comparison to a monoclonal anti-JAG1 antibody AMG 430 in in vitro (human) and in vivo (murine) models. Targeting the Jagged-1/Notch-2 signalling axis by inhalation, exemplified by PRS-400, shows great potential for the treatment of muco-obstructive lung diseases."

Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • FOXA3 • IL13 • IL17A • JAG1 • NOTCH2